Rheumatoid Arthritis Effects on Kidney and Liver and their Correlations with CDAI

Tamara Salman Mohammed; Raya Ezat Maroof; Ali Hussein Al-Hafidh

doi:10.51173/jt.v4i33.698

Authors

Tamara Salman Mohammed Al- Alam Health Centre, Baghdad/ al- Karkh Health Department, Iraqi Ministry of Health
Raya Ezat Maroof College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Ali Hussein Al-Hafidh College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i33.698

Keywords:

RA, B. urea, S. creatinine, GOT, GPT, CDAI

Abstract

Rheumatoid arthritis (RA) is a disease characterized by chronic autoimmune inflammation of body joints, causing movement disability, loss of functions, joint damage, and many complications. Persistent usage of anti-rheumatic drugs has several side effects, which may cause heart, kidney, or liver diseases.

This study aims to assess the influence of RA duration on kidney and liver enzymes and study the correlation between these enzyme levels and RA disease activity (CDAI). This study collected a total of 150 blood samples. 100 samples for RA patients (61 were seropositive, 39 were seronegative), and 50 for healthy Control. throughout the period from November 2021 to February 2022. The blood samples were collected from Baghdad Teaching Hospital / Rheumatology Consulting Clinic. General information had been collected from each subject according to a questionnaire that had been applied for this purpose.

The age groups of patients and control were between 22-72 years, and 26-62 years old, respectively. The female participants were more than the male counterparts. The blood samples were taken from patients and control groups to screen liver and kidney functions by an automated biochemical system using the SELECTRA PRO X2 device, in addition to the ESR test. The study showed that the levels of urea, creatinine, GPT, and GOT were either normal or slightly elevated and they are non-significantly associated with RA disease activity, the little effect of RA on kidney and liver may be related to the low doses of methotrexate and corticosteroid therapy which used mostly for these patients and didn’t reach to toxicity.

Downloads

Download data is not yet available.

References

M. R. Martínez, P. Morán-Álvarez, J. Arroyo-Palomo, M. V. Expósito, And M. V. Díaz, “Rheumatoid Arthritis,” Med., Vol. 13, No. 30, 2021, Doi: 10.1016/J.Med.2021.03.027.

K. P. Machold Et Al., “Very Recent Onset Rheumatoid Arthritis: Clinical And Serological Patient Characteristics Associated With Radiographic Progression Over The First Years Of Disease,” Rheumatology (Oxford)., Vol. 46, No. 2, Pp. 342–349, Feb. 2007, Doi: 10.1093/Rheumatology/Kel237.

V. C. Romão And J. E. Fonseca, “Etiology And Risk Factors For Rheumatoid Arthritis: A State-Of-The-Art Review,” Front. Med., Vol. 8, Nov. 2021, Doi: 10.3389/Fmed.2021.689698.

J. Potempa, P. Mydel, And J. Koziel, “The Case For Periodontitis In The Pathogenesis Of Rheumatoid Arthritis,” Nat. Rev. Rheumatol. 2017 1310, Vol. 13, No. 10, Pp. 606–620, Aug. 2017, Doi: 10.1038/Nrrheum.2017.132.

D. Di Giuseppe, A. Discacciati, N. Orsini, And A. Wolk, “Ra Causes: What Are The Top Causes Of Rheumatoid Arthritis? - Rheumatoidarthritis.Org,” Vol. 16, No. 2, Mar. 2014, Doi: 10.1186/Ar4498.

H. Y. Yap, S. Z. Y. Tee, M. M. T. Wong, S. K. Chow, S. C. Peh, And S. Y. Teow, “Pathogenic Role Of Immune Cells In Rheumatoid Arthritis: Implications In Clinical Treatment And Biomarker Development,” Cells 2018, Vol. 7, Page 161, Vol. 7, No. 10, P. 161, Oct. 2018, Doi: 10.3390/Cells7100161.

C. M. Weyand And J. J. Goronzy, “The Immunology Of Rheumatoid Arthritis,” Nat. Immunol. 2020 221, Vol. 22, No. 1, Pp. 10–18, Nov. 2020, Doi: 10.1038/S41590-020-00816-X.

S. Mori, T. Yoshitama, N. Hirakata, And Y. Ueki, “Prevalence Of And Factors Associated With Renal Dysfunction In Rheumatoid Arthritis Patients: A Cross-Sectional Study In Community Hospitals,” Clin. Rheumatol., Vol. 36, No. 12, Pp. 2673–2682, Dec. 2017, Doi: 10.1007/S10067-017-3804-5/Tables/5.

M. Kochi, K. Kohagura, Y. Shiohira, K. Iseki, And Y. Ohya, “Inflammation As A Risk Of Developing Chronic Kidney Disease In Rheumatoid Arthritis,” Plos One, Vol. 11, No. 8, P. E0160225, Aug. 2016, Doi: 10.1371/Journal.Pone.0160225.

S. Akhlaghi Et Al., “Additional Effect Of Etanercept Or Infliximab On The Liver Function Tests Of Patients With Rheumatoid Arthritis: A Cohort Study,” Ther. Clin. Risk Manag., Vol. 14, P. 1943, 2018, Doi: 10.2147/Tcrm.S172836.

B. Radovanović-Dinić, S. Tešić-Rajković, V. Zivkovic, And S. Grgov, “Clinical Connection Between Rheumatoid Arthritis And Liver Damage,” Rheumatol. Int. 2018 385, Vol. 38, No. 5, Pp. 715–724, Apr. 2018, Doi: 10.1007/S00296-018-4021-5.

E. H. S. O G Segurado, “Vectra Da For The Objective Measurement Of Disease Activity In Patients With Rheumatoid Arthritis - Pubmed,” Oct. 30, 2014. Https://Pubmed.Ncbi.Nlm.Nih.Gov/25365086/ (Accessed Mar. 10, 2022).

A. K. Spencer Et Al., “Validation Of A Machine Learning Approach To Estimate Clinical Disease Activity Index Scores For Rheumatoid Arthritis,” Open, Vol. 7, P. 1781, 2021, Doi: 10.1136/Rmdopen-2021-001781.

L. Siemons, P. M. Ten Klooster, H. E. Vonkeman, P. L. C. M. Van Riel, C. A. W. Glas, And M. A. F. J. Van De Laar, “How Age And Sex Affect The Erythrocyte Sedimentation Rate And C-Reactive Protein In Early Rheumatoid Arthritis,” Bmc Musculoskelet. Disord., Vol. 15, No. 1, Pp. 1–7, Nov. 2014, Doi: 10.1186/1471-2474-15-368/Tables/5.

M. L. Brigden, “Clinical Utility Of The Erythrocyte Sedimentation Rate,” Am. Fam. Physician, Vol. 60, No. 5, Pp. 1443–1450, Oct. 1999.

V. Alende-Castro Et Al., “Factors Influencing Erythrocyte Sedimentation Rate In Adults: New Evidence For An Old Test,” Med. (United States), Vol. 98, No. 34, P. E16816, 2019, Doi: 10.1097/Md.0000000000016816.

M. K. S. Litao And D. Kamat, “Erythrocyte Sedimentation Rate And C-Reactive Protein: How Best To Use Them In Clinical Practice,” Pediatr. Ann., Vol. 43, No. 10, Pp. 417–420, Oct. 2014, Doi: 10.3928/00904481-20140924-10.

P. H. Dessein Et Al., “Traditional And Nontraditional Cardiovascular Risk Factors Are Associated With Atherosclerosis In Rheumatoid Arthritis.,” J. Rheumatol., Vol. 32, No. 3, 2005.

L. Mangnus Et Al., “Studies On Ageing And The Severity Of Radiographic Joint Damage In Rheumatoid Arthritis,” Arthritis Res. Ther., Vol. 17, No. 1, Pp. 1–10, Aug. 2015, Doi: 10.1186/S13075-015-0740-0/Tables/3.

H. A. Getta, N. Khoshnaw, A. F. Alwan, F. A. Sundus, And R. R. Mirza, “Original Article Types Of Anaemia And Its Correlation With Disease Activity In Patients,” Iraqi J. Hematol., Vol. 5, No. 1, Pp. 114–128, 2016.

H. A. Al-Daoseri, M. A. Mohammed Saeed, And R. A. Ahmed, “Prevalence Of Cervical Spine Instability Among Rheumatoid Arthritis Patients In South Iraq,” J. Clin. Orthop. Trauma, Vol. 11, No. 5, Pp. 876–882, Sep. 2020, Doi: 10.1016/J.Jcot.2019.06.013.

N. Al-Ani Et Al., “Clinical Outcomes In Iraqi Patients With Rheumatoid Arthritis Following Earlier Or Later Treatment With Etanercept,” Open Access Rheumatol. Res. Rev., Vol. 13, P. 57, 2021, Doi: 10.2147/Oarrr.S300838.

A. Zink, J. Listing, C. Klindworth, And H. Zeidler, “The National Database Of The German Collaborative Arthritis Centres: I. Structure, Aims, And Patients,” Ann Rheum Dis, Vol. 60, Pp. 199–206, 2001, Doi: 10.1136/Ard.60.3.199.

K. D. Wysham Et Al., “Low Cumulative Disease Activity Is Associated With Higher Bone Mineral Density In A Majority Latinx And Asian Us Rheumatoid Arthritis Cohort,” Semin. Arthritis Rheum., Vol. 53, P. 151972, Apr. 2022, Doi: 10.1016/J.Semarthrit.2022.151972.

R. H. Hussein, I. A. Mezheral-Rayahi, And K. Taha, “Rheumatoid Factor Isotypes In A Sample Of Iraqi Rheumatoid Arthritis Patients,” J. Glob. Pharma Technol., Vol. 10, No. 8, Pp. 141–145, 2018.

Kadhim D J & Gorial F I, “View Of The Belief About Medicines Among A Sample Of Iraqi Patients With Rheumatoid Arthritis,” 2019. Https://Bijps.Uobaghdad.Edu.Iq/Index.Php/Bijps/Article/View/932/806 (Accessed Apr. 16, 2022).

F. Angum, T. Khan, J. Kaler, L. Siddiqui, And A. Hussain, “The Prevalence Of Autoimmune Disorders In Women: A Narrative Review,” Cureus, Vol. 12, No. 5, May 2020, Doi: 10.7759/Cureus.8094.

W. A. Hussein, “The Quality Of Life In Patients With Rheumatoid Arthritis In Baghdad,2017: A Cross-Sectional Study,” Int. J. Med. Res. Heal. Sci., Vol. 6, No. 11, Pp. 20–34, 2017.

R. A. Sakini, I. K. Abdul-Zehra, And M. S. M. Al-Nimer, “Neuropathic Manifestations In Rheumatoid Arthritis: A Clinical And Electrophysiological Assessment In A Small Sample Of Iraqi Patients,” Ann. Saudi Med., Vol. 25, No. 3, Pp. 247–249, 2005, Doi: 10.5144/0256-4947.2005.247.

T. Pincus, L. F. Callahan, W. G. Sale, A. L. Brooks, L. E. Payne, And W. K. Vaughn, “Severe Functional Declines, Work Disability, And Increased Mortality In Seventy‐Five Rheumatoid Arthritis Patients Studied Over Nine Years,” Arthritis Rheum., Vol. 27, No. 8, Pp. 864–872, 1984, Doi: 10.1002/Art.1780270805.

R. Ahmad And A. Zgair, “Immunological And Biological Manifestation Of Rheumatoid Arthritis Patient In Iraq,” 2021.

D. A. Guadagnin, L. V. Mazzali, T. L. Skare, And B. S. Kahlow, “Treating Rheumatoid Arthritis With Leflunomide Monotherapy Versus Combination Therapy With Methotrexate,” Eur. J. Rheumatol., Vol. 8, No. 1, P. 12, Jan. 2021, Doi: 10.5152/Eurjrheum.2020.20113.

C. A. Isnardi Et Al., “Pos0312 How Does The Presence Of Depression Impact On Disease Activity Scores In Patients With Rheumatoid Arthritis?,” Ann. Rheum. Dis., Vol. 80, No. Suppl 1, Pp. 382–382, Jun. 2021, Doi: 10.1136/Annrheumdis-2021-Eular.1374.

P. Vasanthi, G. Nalini, And G. Rajasekhar, “Status Of Oxidative Stress In Rheumatoid Arthritis,” Int. J. Rheum. Dis., Vol. 12, No. 1, Pp. 29–33, Apr. 2009, Doi: 10.1111/J.1756-185x.2009.01375.X.

J. M. Jou, “Erythrocyte Sedimentation Rate (Esr),” Lab. Hematol. Pract., Pp. 638–646, Aug. 2012, Doi: 10.1002/9781444398595.Ch49.

M. Couderc Et Al., “Prevalence Of Renal Impairment In Patients With Rheumatoid Arthritis: Results From A Cross-Sectional Multicenter Study,” Arthritis Care Res. (Hoboken)., Vol. 68, No. 5, Pp. 638–644, 2016, Doi: 10.1002/Acr.22713.

H. R. Tawfeeq And J. M. J. Ali, “Assessment Of Liver Enzymes Activity In Patients With Rheumatoid Arthritis In Nineveh Province,” Vol. 8, No. 2, Pp. 278–284, 2012.

J. Kay Et Al., “Clinical Disease Activity And Acute Phase Reactant Levels Are Discordant Among Patients With Active Rheumatoid Arthritis: Acute Phase Reactant Levels Contribute Separately To Predicting Outcome At One Year,” Arthritis Res. Ther., Vol. 16, No. 1, Pp. 1–10, Feb. 2014, Doi: 10.1186/Ar4469/Tables/6.

W. J. Martin Et Al., “Older Age Of Rheumatoid Arthritis Onset And Comorbidities Correlates With Less Haq-Di And Cdai Response To Etanercept In The Radius 2 Registry,” J. Clin. Rheumatol., Vol. 20, No. 6, P. 301, 2014, Doi: 10.1097/Rhu.0000000000000152.

M. West, R. M. Poske, A. B. Black, C. G. Pilz, And H. J. Zimmerman, “Enzyme Activity In Synovial Fluid,” J. Lab. Clin. Med., Vol. 62, No. 2, Pp. 175–183, Aug. 1963, Doi: 10.5555/Uri:Pii:0022214363900556.

D. Daoussis Et Al., “Cardiovascular Risk Factors And Not Disease Activity, Severity Or Therapy Associate With Renal Dysfunction In Patients With Rheumatoid Arthritis,” Ann. Rheum. Dis., Vol. 69, No. 3, Pp. 517–521, Mar. 2010, Doi: 10.1136/Ard.2008.105049.

M. Farr, D. L. Scott, T. J. Constable,’, R. J. Hawker,’, C. F. Hawkins,’ And, And J. Stuart3, “Thrombocytosis Of Active Rheumatoid Disease,” Ann. Rheum. Dis., Vol. 42, Pp. 545–549, 1983, Doi: 10.1136/Ard.42.5.545.